Vice President, Early Development
Adam is a biopharma executive with extensive expertise in clinical, regulatory, non-clinical, CMC and commercial sciences. He will lead Aceragen’s Early Development activities, such as the identification and development of novel indications for our current pipeline programs. He will also direct evaluation and support of new opportunities that fit within Aceragen’s mission to address rare or orphan rheumatologic and pulmonary disease. Aceragen is honored to have him and his more than fifteen years of experience directing drug development from pre-IND to NDA/BLA submission and post-marketing commitments.
Recently, Adam licensed intellectual property of his own design to Takeda in a milestone-based acquisition. Adam served in strategic R&D positions at Amgen and Baxter Bioscience and led R&D for a small publicly traded pharmaceutical company. He served in the U.S. Army for more than four years. In 2001, Adam received his PhD in neuroscience from Louisiana State University.